Analysts Set Expectations for RCUS FY2025 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Arcus Biosciences in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($5.29) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.06. The firm had revenue of $48.00 million for the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The business’s quarterly revenue was up 50.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.94) earnings per share.

A number of other brokerages also recently weighed in on RCUS. Barclays boosted their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Wells Fargo & Company assumed coverage on Arcus Biosciences in a report on Tuesday, October 8th. They set an “overweight” rating and a $29.00 price objective on the stock. Finally, HC Wainwright restated a “neutral” rating and set a $20.00 price target on shares of Arcus Biosciences in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Arcus Biosciences currently has an average rating of “Buy” and a consensus target price of $34.00.

Arcus Biosciences Price Performance

RCUS stock opened at $13.32 on Wednesday. The company has a market capitalization of $1.22 billion, a P/E ratio of -4.23 and a beta of 0.87. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. Arcus Biosciences has a 52-week low of $12.88 and a 52-week high of $20.31. The business has a 50-day simple moving average of $15.35 and a two-hundred day simple moving average of $15.90.

Insider Buying and Selling at Arcus Biosciences

In related news, CFO Robert C. Goeltz II sold 3,594 shares of Arcus Biosciences stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the sale, the chief financial officer now directly owns 60,138 shares in the company, valued at $902,070. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its holdings in shares of Arcus Biosciences by 6.9% during the third quarter. FMR LLC now owns 4,467,557 shares of the company’s stock valued at $68,309,000 after purchasing an additional 286,766 shares in the last quarter. Point72 Asset Management L.P. raised its position in Arcus Biosciences by 32.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,437,073 shares of the company’s stock worth $37,263,000 after buying an additional 603,222 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in Arcus Biosciences by 146.9% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock valued at $15,684,000 after acquiring an additional 610,219 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Arcus Biosciences by 25.1% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock valued at $14,236,000 after acquiring an additional 186,750 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Arcus Biosciences by 11.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock worth $8,669,000 after acquiring an additional 59,536 shares during the period. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.